References
- Chua S-S, Wong I CK, Edmondson H, Allen C, Chow J, Peacham J, Hill G, Grantham J. A feasibility study for recording of dispensing errors and ‘near misses’ in four UK primary care pharmacies. Drug Safety 2003; 26:803–813, [PUBMED], [INFOTRIEVE], [CSA]
- Seifert S A, Jacobitz K. Pharmacy prescription dispensing errors reported to a regional poison control centre. J Toxicol, Clin Toxicol 2002; 40:919–923, [CROSSREF], [CSA]
- Oertel R, Richter K, Ebert U, Kirch W. Determination of scopolamine in human serum and microdialysis samples by chromatography-tandem mass spectrometry. J Chromatogr, B 2001; 750:121–128, [CSA]
- Grasha A F, Schell K. Psychosocial factors, workload, and human error in a simulated pharmacy dispensing task. Percept Mot Skills 2001; 92:53–71, [PUBMED], [INFOTRIEVE], [CSA]
- Antimuscarinics/antispasmodics. In: McEvoy G K, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 2001:1180–1211.
- Ebert U, Siepmann M, Oertel R, Wesnes K A, Kirch W. Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. J Clin Pharmacol 1998; 38:720–726, [PUBMED], [INFOTRIEVE], [CSA]
- Dahl E, Offer-Ohlsen D, Lillevold P E, Sandvik L. Transdermal scopolamine, oral meclizine, and placebo in motion sickness. Clin Pharmacol Ther 1984; 36:116–120, [PUBMED], [INFOTRIEVE], [CSA]
- Kanto J, Kentala E, Kaila T, Pihlajamäki K. Pharmacokinetics of scopolamine during caesarean section: relationship between serum concentration and effect. Acta Anaesthesiol Scand 1989; 33:482–486, [PUBMED], [INFOTRIEVE], [CSA]
- Anderson S, McGuire R, McKeown D. Comparison of the cognitive effects of premedication with hyoscine and atropine. Br J Anaesth 1985; 57:169–173, [PUBMED], [INFOTRIEVE], [CSA]
- Wick H. Enteral absorption of hyoscine N-butylbromide. J Pharm Pharmacol 1967; 19:779, [PUBMED], [INFOTRIEVE], [CSA]
- Vapaatalo H, Pentillä A, Kaltiala E. The absorption and elimination of orally administered [14C]hyoscine N-butylbromide (butylscopolamine). J Pharm Pharmacol 1975; 27:542–543, [PUBMED], [INFOTRIEVE], [CSA]
- Pomeroy A R, Rand M J. Anticholinergic effects and passage through the intestinal wall of N-butylhyoscine bromide. J Pharm Pharmacol 1969; 21:180–187, [PUBMED], [INFOTRIEVE], [CSA]
- Rupreht J. Hyoscine derivative in children—but was it hyoscine?Anaesthesia 1991; 46:514, [PUBMED], [INFOTRIEVE], [CSA]
- Reid K, Palmer J L, Wright R J, Clemes S A, Troakes C, Somal H S, House F, Stott J RR. Comparison of the neurokinin-I antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man. Br J Clin Pharmacol 2000; 50:61–64, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sissons G RJ, McQueenie A, Mantle M. The ocular effects of hyoscine-n-butylbromide (“buscopan”) in radiological practice. Br J Radiol 1991; 64:584–586, [PUBMED], [INFOTRIEVE], [CSA]
- Ritchie J A, Truelove S C. Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. BMJ 1979; 1:376–378, [PUBMED], [INFOTRIEVE], [CSA]
- Nachum Z, Shahal B, Shupak A, Spitzer O, Gonen A, Beiran I, Lavon H, Eynan M, Dachir S, Levy A. Scopolamine bioavailability in combined oral and transdermal delivery. J Pharmacol Exp Ther 2001; 296:121–123, [PUBMED], [INFOTRIEVE], [CSA]
- Kentala E, Kaila T, Arola M, Matilla M, Kanto J. Pharmacokinetics and clinical response of hyoscine plus morphine premedication in connection with cardiopulmonary bypass surgery. Eur J Anaesth 1991; 8:135–140, [CSA]
- Tilleul P, Mons B, Schmitt C, Lamorte J M, Begue D. Intravenous drug preparation practices: a survey in a French university hospital. Pharm World Sci 2003; 25:276–279, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Catterson M L, Martin R L. Anticholinergic toxicity masquerading as neuroleptic malignant syndrome: a case report and review. Ann Clin Psychiatry 1994; 6:267–269, [PUBMED], [INFOTRIEVE], [CSA]
- Lauwers L F, Daelemans R, Baute L, Verbraeken H. Scopolamine intoxications. Intensive Care Med 1983; 9:283–285, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Beaver K M, Gavin T J. Treatment of acute anticholinergic poisoning with physostigmine. Am J Emerg Med 1998; 16:505–507, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Osterholm R K, Camoriano J K. Transdermal scopolamine psychosis. JAMA 1982; 247:3081, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rodysill K J, Warren J B. Transdermal scopolamine and toxic psychosis. Ann Intern Med 1983; 98:561, [PUBMED], [INFOTRIEVE], [CSA]
- Perrone J, Shaw L, De Roos F. Laboratory confirmation of scopolamine co-intoxication in patients using tainted heroin. J Toxicol, Clin Toxicol 1999; 37:491–946, [CROSSREF], [CSA]
- Kumar C M. Unattended continuous infusion of hyoscine leading to delayed visual disturbances. Can J Anaesth 1994; 41:551, [PUBMED], [INFOTRIEVE], [CSA]
- Danks J L. Hyoscine derivatives in children. Anaesthesia 1990; 45:1089, [PUBMED], [INFOTRIEVE], [CSA]
- Muttray A, Maier W, Vogt T, Demuth W, Konietzko J. Enzephalopathie nach intoxication mit einem anticholinergicum. Dtsch Med Wochenschr 1994; 119:731, [PUBMED], [INFOTRIEVE], [CSA]
- Tsao J W, Heilman K M. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 2003; 349:2274–2275, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Buylaert W, Van Sassenbroeck D, Verstraete A, Hemelsoet D, Monsieurs K. A pharmacy dispensing error leading to hyoscine hydrobromide overdoses. Br J Clin Pharmacol 2005; 59:123–124, [CROSSREF], [CSA]